

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>5AM Ventures IV, L.P.</u> <hr/> (Last) (First) (Middle) <u>501 2ND STREET, SUITE 350</u> <hr/> (Street) <u>SAN FRANCISCO CA 94107</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/17/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>Crinetics Pharmaceuticals, Inc. [CRNX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	2,797,635	(1)	I	See footnotes ⁽²⁾⁽⁴⁾
Series B Preferred Stock	(1)	(1)	Common Stock	451,274	(1)	I	See footnotes ⁽²⁾⁽⁴⁾
Series A Preferred Stock	(1)	(1)	Common Stock	116,567	(1)	I	See footnotes ⁽³⁾⁽⁴⁾
Series B Preferred Stock	(1)	(1)	Common Stock	18,802	(1)	I	See footnotes ⁽³⁾⁽⁴⁾

1. Name and Address of Reporting Person* <u>5AM Ventures IV, L.P.</u> <hr/> (Last) (First) (Middle) <u>501 2ND STREET, SUITE 350</u> <hr/> (Street) <u>SAN FRANCISCO CA 94107</u> <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>5AM Co-Investors IV, L.P.</u> <hr/> (Last) (First) (Middle) <u>501 2ND STREET, SUITE 350</u> <hr/> (Street) <u>SAN FRANCISCO CA 94107</u> <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*		
5AM Partners IV, LLC		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO CA		94107
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
ROCKLAGE SCOTT M		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO CA		94107
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
DIEKMAN JOHN D		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO CA		94107
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Schwab Andrew J.		
(Last)	(First)	(Middle)
501 2ND STREET, SUITE 350		
(Street)		
SAN FRANCISCO CA		94107
(City) (State) (Zip)		

Explanation of Responses:

1. The Series A Preferred Stock and Series B Preferred Stock is convertible into the Issuer's Common Stock on a 3.29-for-1 basis at the holder's election and has no expiration date. The Series A Preferred Stock and Series B Preferred Stock will automatically convert into Common Stock immediately prior to the closing of the Issuer's initial public offering.
2. The 9,204,220 shares of Series A Preferred Stock and 1,484,690 shares of Series B Preferred Stock are held by 5AM Ventures IV, L.P. ("Ventures IV").
3. The 383,507 shares of Series A Preferred Stock and 61,861 shares of Series B Preferred Stock are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV").
4. 5AM Partners IV, LLC is the sole general partner of Ventures IV and Co-Investors IV (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM Funds. Each of Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

[5AM VENTURES IV, L.P. By:](#)
[5AM Partners IV, LLC, its](#)
[General Partner /s/ Scott M.](#) 07/17/2018
[Rocklage Managing Member](#)
[5AM CO-INVESTORS IV, L.P.](#)
[By: 5AM Partners IV, LLC, its](#)
[General Partner /s/ Scott M.](#) 07/17/2018
[Rocklage Managing Member](#)
[5AM PARTNERS IV, LLC /s/](#)
[Scott M. Rocklage Managing](#) 07/17/2018
[Member](#)
[/s/ Scott M. Rocklage](#) 07/17/2018

/s/ John D. Diekman 07/17/2018

/s/ Andrew J. Schwab 07/17/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.